Reports Q3 revenue $0.5M vs. $0.7M last year. The company said, “The Company made continued progress towards commercial adoption with inclusion of KidneyIntelX in clinical guidelines, issuance of a Medicare coverage draft, performance of new direct to physician sales force, April launch of U.S. Food and Drug Administration De Novo authorized kidneyintelX.dkd, and release of new real-world outcomes evidence. Optimization of shareholder value continues with year over year significant expense reductions, completion of equity financing, and the initiation of a strategic sale process.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNLX:
- Is RNLX a Buy, Before Earnings?
- Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
- Renalytix AI Announces Fundraising, Executive Changes, and Shareholder Approval
- Renalytix files to sell 19.99M ordinary shares for holders
- Renalytix AI Announces Convertible Bond Repayments and Share Issuance